Trials / Completed
CompletedNCT00935389
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
Prospective Control Study of TW in the Treatment of LN Type V With Gross Proteinuria
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Nanjing University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
Detailed description
Compared with cyclophosphamide(CTX), to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) in LN-V patients with gross proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tripterygium glycosides | The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d. |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-04-01
- Completion
- 2011-05-01
- First posted
- 2009-07-09
- Last updated
- 2011-08-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00935389. Inclusion in this directory is not an endorsement.